JayaBio News
Jaya Biosciences Joins Taking the Pulse - A Health Care and Life Sciences Podcast
Our CEO Pawel Krysiak and CSO Neal Goodwin, PhD, joined Taking the Pulse - A Health Care and Life Sciences Podcast to discuss JayaBio’s work in a precision medicine platform aiming to stop progression in Alzheimer’s, Parkinson’s, and frontotemporal dementia.
August 12, 2025
Our CEO Pawel Krysiak and CSO Neal Goodwin, PhD, joined Taking the Pulse - A Health Care and Life Sciences Podcast to discuss JayaBio’s work in a precision medicine platform aiming to stop progression in Alzheimer’s, Parkinson’s, and frontotemporal dementia.
They share how the team is using precision medicine to target specific mutations linked to Alzheimer’s, Parkinson’s, and frontotemporal dementia, aiming to arrest disease progression with a single dose. The conversation explores how gene therapy works, what makes JayaBio’s approach different, and more.
Jaya Biosciences Executive Team Meets with South Carolina Government
Our executive team had the honor of meeting with Hon. Lieutenant Governor of South Carolina, Pamela Everette.
January 29, 2025
Our executive team had the honor of meeting with Hon. Lieutenant Governor of South Carolina, Pamela Everette, Deputy Director of Commerce Ashely Teasdel, and Senior Manager of Global Business Development Philip Morgan to discuss a potential partnership with Jaya Biosciences to advance breakthrough therapies for Alzheimer’s disease and related dementias and to strengthen South Carolina’s rapidly growing life sciences sector.
We extend our heartfelt thanks for a warm welcome and productive discussion.
Jaya Biosciences Completes Inaugural SCbioDrive Accelerator Program
We are proud to announce the successful completion of SCbioDrive, an accelerator program for emerging life sciences companies organized by SCbio in partnership with MassBio. JayaBio was one of seven oncology and neuroscience startups selected to be a part of the inaugural cohort.
November 22, 2024
We are proud to announce the successful completion of SCbioDrive, an accelerator program for emerging life sciences companies organized by SCbio in partnership with MassBio. JayaBio was one of seven oncology and neuroscience startups selected to be a part of the inaugural cohort.
Over the past eight weeks, JayaBio had the opportunity to connect with industry mentors, refine our strategies, and showcase our innovative approach to tackling neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, and frontotemporal dementia.
“We were very impressed with the organization and quality of the SCbioDrive accelerator program. It has been an invaluable experience for our team, providing us with additional tools and insights to advance our mission of addressing unmet needs in neurodegenerative diseases,” said Pawel Krysiak, President and CEO of JayaBio.
“We are especially grateful for the guidance we received from leaders at Axonis, Eli Lilly and Sanofi. Their industry expertise and actionable insights will positively shape our approach to developing JB111 for PPT1-associated Alzheimer’s disease,” added Dr. Neal Goodwin, JayaBio’s Chief Scientific Officer.
During Demo Week, the inaugural cohort companies met with mentors and refined pitches in preparation for Demo Day, an end-of-program event where we presented our science to a diverse group of investors and other stakeholders.
Jaya Biosciences: Neuroscience Startup Chosen for SCbioDrive Accelerator Program
Jaya Biosciences was highlighted in a press release by SCbio for our work in developing CNS-directed gene therapies for neurodegenerative diseases like Alzheimer’s, Parkinson’s, and frontotemporal dementia as we begin the inaugural SCbioDrive Accelerator Program.
September 30, 2024
Jaya Biosciences was highlighted in a press release by SCbio for our work in developing CNS-directed gene therapies for neurodegenerative diseases like Alzheimer’s, Parkinson’s, and frontotemporal dementia as we begin the inaugural SCbioDrive Accelerator Program.
SCbio’s release details our focus on targeting upstream effector pathways and lysosomal dysfunction to address the potential root causes of these conditions, our precision medicine approach to targeting lysosomal gene mutations, our research suggesting that Alzheimer’s is likely a heterogeneous disease with distinct subpopulations, and more.
Read SCbio’s press release here: https://www.scbio.org/jaya-biosciences-neuroscience-startup-chosen-for-scbiodrive-accelerator-program/
Jaya Biosciences Has Been Selected for the Inaugural SCbioDrive Cohort of Highly Promising Oncology and Neuroscience Startups
This program will support our efforts to advance groundbreaking innovations in neurodegeneration alongside other exceptional early-stage companies.
September 9, 2024
We're thrilled to announce that SCbio has selected Jaya Biosciences to be a member of the SCbioDrive Accelerator program. SCbio, in partnership with The Massachusetts Biotechnology Council, has selected seven emerging life sciences companies to participate in the inaugural SCbioDrive Accelerator cohort. This program will support our efforts in to advance groundbreaking innovations in neurodegeneration alongside other exceptional early-stage companies.